Discriminating cocaine use from other sympathomimetics using wearable electrocardiographic (ECG) sensors.

Humans Sympathomimetics Electrocardiography Cocaine-Related Disorders / diagnosis Cocaine Methylphenidate Wearable Electronic Devices
Addictive behaviors Cocaine detection Cocaine use disorder Electrocardiography Exercise Methylphenidate Remote wireless sensors Substance-related disorders Tobacco

Journal

Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587

Informations de publication

Date de publication:
01 09 2023
Historique:
received: 28 12 2022
revised: 05 06 2023
accepted: 09 07 2023
medline: 22 8 2023
pubmed: 1 8 2023
entrez: 31 7 2023
Statut: ppublish

Résumé

Our group has established the feasibility of using on-body electrocardiographic (ECG) sensors to detect cocaine use in the human laboratory. The purpose of the current study was to test whether ECG sensors and features are capable of discriminating cocaine use from other non-cocaine sympathomimetics. Eleven subjects with cocaine use disorder wore the Zephyr BioHarness™ 3 chest band under six experimental (drug and non-drug) conditions, including 1) laboratory, intravenous cocaine self-administration, 2) after a single oral dose of methylphenidate, 3) during aerobic exercise, 4) during tobacco use (N=7 who smoked tobacco), and 5) during routine activities of daily inpatient living (unit activity). Three ECG-derived feature sets served as primary outcome measures, including 1) the RR interval (i.e., heart rate), 2) a group of ECG interval proxies (i.e., PR, QS, QT and QTc intervals), and 3) the full ECG waveform. Discriminatory power between cocaine and non-cocaine conditions for each of the three outcomes measures was expressed as the area under the receiver operating characteristics (AUROC) curve. All three outcomes successfully discriminated cocaine use from unit activity, exercise, tobacco, and methylphenidate conditions with a mean AUROC values ranging from 0.66 to 0.99 and with least squares means values all statistically different/higher than 0.5 among all subjects [F(3, 99) = 3.38, p =0.02] and among those with tobacco use [F(4, 84) = 5.39, p = 0.0007]. These preliminary results support discriminatory power of wearable ECG sensors for detecting cocaine use.

Sections du résumé

BACKGROUND
Our group has established the feasibility of using on-body electrocardiographic (ECG) sensors to detect cocaine use in the human laboratory. The purpose of the current study was to test whether ECG sensors and features are capable of discriminating cocaine use from other non-cocaine sympathomimetics.
METHODS
Eleven subjects with cocaine use disorder wore the Zephyr BioHarness™ 3 chest band under six experimental (drug and non-drug) conditions, including 1) laboratory, intravenous cocaine self-administration, 2) after a single oral dose of methylphenidate, 3) during aerobic exercise, 4) during tobacco use (N=7 who smoked tobacco), and 5) during routine activities of daily inpatient living (unit activity). Three ECG-derived feature sets served as primary outcome measures, including 1) the RR interval (i.e., heart rate), 2) a group of ECG interval proxies (i.e., PR, QS, QT and QTc intervals), and 3) the full ECG waveform. Discriminatory power between cocaine and non-cocaine conditions for each of the three outcomes measures was expressed as the area under the receiver operating characteristics (AUROC) curve.
RESULTS
All three outcomes successfully discriminated cocaine use from unit activity, exercise, tobacco, and methylphenidate conditions with a mean AUROC values ranging from 0.66 to 0.99 and with least squares means values all statistically different/higher than 0.5 among all subjects [F(3, 99) = 3.38, p =0.02] and among those with tobacco use [F(4, 84) = 5.39, p = 0.0007].
CONCLUSIONS
These preliminary results support discriminatory power of wearable ECG sensors for detecting cocaine use.

Identifiants

DOI: 10.1016/j.drugalcdep.2023.110898 PMID: 37523916
pubmed: 37523916
pii: S0376-8716(23)01136-5
doi: 10.1016/j.drugalcdep.2023.110898
pii:
doi:

Substances chimiques

Sympathomimetics 0
Cocaine I5Y540LHVR
Methylphenidate 207ZZ9QZ49

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

110898

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA033733
Pays : United States

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no conflicts of interest.

Auteurs

Gustavo A Angarita (GA)

Department of Psychiatry, Yale University School of Medicine, New Haven, CT06519, USA; Clinical Neuroscience Research Unit, Connecticut Mental Health Center, 34 Park Street, New Haven, CT06519, USA; Connecticut Mental Health Center, New Haven, CT06519, USA; Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT06510, USA. Electronic address: Gustavo.angarita@yale.edu.

Brian Pittman (B)

Department of Psychiatry, Yale University School of Medicine, New Haven, CT06519, USA; Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT06510, USA.

Annamalai Nararajan (A)

Philips Research North America, Cambridge, MA02141, USA; Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT06510, USA.

Talia F Mayerson (TF)

Department of Psychiatry, Yale University School of Medicine, New Haven, CT06519, USA; Clinical Neuroscience Research Unit, Connecticut Mental Health Center, 34 Park Street, New Haven, CT06519, USA; Connecticut Mental Health Center, New Haven, CT06519, USA; Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT06510, USA.

Abhinav Parate (A)

Manning College of Information and Computer Science, University of Massachusetts, Amherst, MA01003, USA; Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT06510, USA; Lumme Health Inc, Boston, MA02210, USA.

Benjamin Marlin (B)

Manning College of Information and Computer Science, University of Massachusetts, Amherst, MA01003, USA; Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT06510, USA.

Ralitza R Gueorguieva (RR)

Department of Biostatistics, Yale University School of Public Health, New Haven, CT06510, USA; Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT06510, USA.

Marc N Potenza (MN)

Department of Psychiatry, Yale University School of Medicine, New Haven, CT06519, USA; Connecticut Mental Health Center, New Haven, CT06519, USA; Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT06510, USA; Child Study Center, Yale University School of Medicine, New Haven, CT06510, USA; Department of Neuroscience, Yale University, New Haven, CT06510, USA; Connecticut Council on Problem Gambling, Wethersfield, CT06109, USA; Wu Tsai Institute, New Haven, CT06510, USA.

Deepak Ganesan (D)

Manning College of Information and Computer Science, University of Massachusetts, Amherst, MA01003, USA; Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT06510, USA.

Robert T Malison (RT)

Department of Psychiatry, Yale University School of Medicine, New Haven, CT06519, USA; Clinical Neuroscience Research Unit, Connecticut Mental Health Center, 34 Park Street, New Haven, CT06519, USA; Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT06510, USA; Department of Neuroscience, Yale University, New Haven, CT06510, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Discriminating cocaine use from other...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents du système nerveux périphérique › Agents du système nerveux autonome › Sympathomimétiques › Discriminating cocaine use from other...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Électrodiagnostic › Électrocardiographie › Discriminating cocaine use from other...
questionsmedicales.fr › Troubles mentaux › Troubles liés à une substance › Troubles liés à la cocaïne › Discriminating cocaine use from other...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques, cycle ponté › Tropanes › Cocaïne › Discriminating cocaine use from other...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pipéridines › Méthylphénidate › Discriminating cocaine use from other...
questionsmedicales.fr › Équipement et fournitures › Équipement et fournitures électriques › Dispositifs électroniques portables › Discriminating cocaine use from other...